Sarilumab is indicated for:
Population group: only adults (18 years old or older)
Sarilumab in combination with methotrexate (MTX) is indicated for the treatment of moderately to severely active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Sarilumab can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriat.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Sarilumab is contraindicated in the following cases:
Ā© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
